# David W. Boulton

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/david-w-boulton/

## Facts

| Field | Value |
| --- | --- |
| Citations | 7,268 |
| Field | Diabetes Treatment and Management |
| h-index | 45 |
| i10-index | 113 |
| Last Known Institution | AstraZeneca (South Korea) |
| OpenAlex ID | https://openalex.org/A5060128890 |
| ORCID iD | 0000-0002-0668-7304 |
| Works | 197 |

## Researcher papers

- [Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes](https://scholariq.org/papers/effect-of-dapagliflozin-on-worsening-heart-failure-and-cardiovascular-death-in/)
- [Why do <scp>SGLT2</scp> inhibitors reduce heart failure hospitalization? <scp>A</scp> differential volume regulation hypothesis](https://scholariq.org/papers/why-do-scp-sglt2-scp-inhibitors-reduce-heart-failure-hospitalization-scp-a-scp/)
- [Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects](https://scholariq.org/papers/dapagliflozin-a-novel-sglt2-inhibitor-induces-dose-dependent-glucosuria-in/)
- [Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes](https://scholariq.org/papers/characterization-of-renal-glucose-reabsorption-in-response-to-dapagliflozin-in/)
- [Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2](https://scholariq.org/papers/clinical-pharmacokinetics-and-pharmacodynamics-of-dapagliflozin-a-selective/)
- [In vitro P-glycoprotein affinity for atypical and conventional antipsychotics](https://scholariq.org/papers/in-vitro-p-glycoprotein-affinity-for-atypical-and-conventional-antipsychotics/)
- [Extensive Binding of the Bioflavonoid Quercetin to Human Plasma Proteins](https://scholariq.org/papers/extensive-binding-of-the-bioflavonoid-quercetin-to-human-plasma-proteins/)
- [Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF](https://scholariq.org/papers/dapagliflozin-and-diuretic-use-in-patients-with-heart-failure-and-reduced/)
- [Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers](https://scholariq.org/papers/effect-of-st-john-s-wort-hypericum-perforatum-on-cytochrome-p-450-2d6-and-3a4/)
- [Interaction Between the Sodium‐Glucose–Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects](https://scholariq.org/papers/interaction-between-the-sodium-glucose-linked-transporter-2-inhibitor/)
- [Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A <i>post hoc</i> analysis of the <scp>EXSCEL</scp> trial](https://scholariq.org/papers/effect-of-once-weekly-exenatide-on-estimated-glomerular-filtration-rate-slope/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Pharmacogenetics and Drug Metabolism](https://scholariq.org/topics/pharmacogenetics-and-drug-metabolism/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)

## Researcher university

- [AstraZeneca (South Korea)](https://scholariq.org/institutions/astrazeneca-south-korea/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.